OTCMKTS:RHHBY
Roche Holding AG Stock News
$34.53
+0.500 (+1.47%)
At Close: Jun 13, 2024
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
01:01pm, Monday, 10'th Jun 2024
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
Roche Diagnostics Company Profile 2024, Featuring a Detailed Product Pipeline Analysis and Ongoing Clinical Trials Insights
07:44am, Monday, 10'th Jun 2024
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Roche Diagnostics International Ltd - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This r
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
01:05am, Monday, 10'th Jun 2024
Basel, 10 June 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its cobas® liat SARS-CoV-
European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new 5-year data confirming the sustained efficacy and safety profile
Basel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new five-year data confirming the sustained efficacy and safety profile of Evrysdi® (risdiplam) in children with Type 1 spinal
Roche's head of cardiovascular disease dissects GLP-1 drug trial results
06:16pm, Wednesday, 05'th Jun 2024
Manu Chakravarthy, Roche SVP & global head of cardiovascular disease, joins 'Fast Money' to talk the company's recent weight-loss drug trial results.
There's still a lot of optimism in Indian assets, says David Roche
06:15am, Wednesday, 05'th Jun 2024
David Roche, strategist at Quantum Strategy, discusses India's election results.
Roche's (RHHBY) Inavolisib NDA Gets FDA Priority Review Tag
12:30pm, Wednesday, 29'th May 2024
The FDA grants priority review to Roche's (RHHBY) NDA for the inavolisib combination regimen for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
FDA grants Priority Review to Roche's inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
01:00am, Wednesday, 29'th May 2024
Basel, 29 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application and granted Priority Review to
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
01:00am, Monday, 27'th May 2024
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwide Upcoming launches of
Changes to the Roche Enlarged Corporate Executive Committee
01:00am, Monday, 27'th May 2024
Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after fourteen years with the company.
Analog Devices CEO Vincent Roche on Q2 earnings
12:30pm, Wednesday, 22'nd May 2024
Analog Devices CEO Vincent Roche joins CNBC's 'Money Movers' to discuss the company's earnings report, implementing AI, and more.
Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
01:00am, Wednesday, 22'nd May 2024
Basel, 22 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Admi